Table 2.
Comparison of Proportion of Participants with Pathologic Parameters in Weight, Fasting Glucose, and Lipid Levels at Baseline and at 10-Year Follow-up in Each Patient Group
| Baseline | 10-year follow-up | ||||
|---|---|---|---|---|---|
| % (n) | % (n) | % difference | n | P a | |
| BMI ≥30 kg/m2 | |||||
| Discontinued group | 3.7 (1) | 22.2 (6) | 18.5 | 27 | .063 |
| Antipsychotic group | 7.3 (11) | 38.4 (58) | 31.1 | 151 | <.001 |
| Total | 6.7 (12) | 36.0 (64) | 29.3 | 178 | <.001 |
| Glucose >110 mg/dL | |||||
| Discontinued group | 0 (0) | 6.5 (2) | 6.5 | 31 | — |
| Antipsychotic group | 1.8 (3) | 7.3 (12) | 5.5 | 165 | .022 |
| Total | 1.5 (3) | 7.1 (14) | 5.6 | 196 | .007 |
| Insulin (µU/mL); men >15.7, women >17.3 | |||||
| Discontinued group | 0 (0) | 10.5 (2) | 10.5 | 19 | — |
| Antipsychotic group | 10.7 (12) | 34.8 (39) | 24.1 | 112 | <.001 |
| Total | 9.2 (12) | 31.3 (41) | 22.1 | 131 | <.001 |
| HOMA; men >3.5, women >3.9 | |||||
| Discontinued group | 0 (0) | 10.5 (2) | 10.5 | 19 | — |
| Antipsychotic group | 8.2 (9) | 33.6 (37) | 25.4 | 110 | <.001 |
| Total | 7.0 (9) | 30.2 (39) | 23.2 | 129 | <0.001 |
| Triglyceride/HDL index >3.5 | |||||
| Discontinued group | 8.0 (2) | 4.0 (1) | 4.0 | 25 | 1.000 |
| Antipsychotic group | 11.5 (16) | 27.3 (38) | 15.8 | 139 | <.001 |
| Total | 11.0 (18) | 23.8 (39) | 12.8 | 164 | <.001 |
| Cholesterol >200 mg/dL | |||||
| Discontinued group | 19.4 (6) | 38.7 (12) | 19.3 | 31 | .070 |
| Antipsychotic group | 24.1 (40) | 42.2 (70) | 18.1 | 166 | <.001 |
| Total | 23.4 (46) | 41.6 (82) | 18.2 | 197 | <.001 |
| LDL cholesterol >130 mg/dL | |||||
| Discontinued group | 19.2 (5) | 34.6 (9) | 15.4 | 26 | .219 |
| Antipsychotic group | 25.2 (35) | 35.3 (49) | 10.1 | 139 | .024 |
| Total | 24.2 (40) | 35.2 (58) | 11.0 | 165 | .006 |
| HDL cholesterol <40 mg/dL | |||||
| Discontinued group | 23.1 (6) | 15.4 (4) | −7.7 | 26 | .625 |
| Antipsychotic group | 21.1 (30) | 28.2 (40) | 7.1 | 142 | .143 |
| Total | 21.4 (36) | 26.2 (44) | 4.8 | 168 | .280 |
| Triglycerides >150 mg/dL | |||||
| Discontinued group | 3.7 (1) | 7.4 (2) | 3.7 | 27 | 1.000 |
| Antipsychotic group | 7.8 (11) | 27.7 (39) | 19.9 | 141 | <.001 |
| Total | 7.1 (12) | 24.4 (41) | 17.3 | 168 | <.001 |
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.
aMcNemar test for repeated measures.